168 related articles for article (PubMed ID: 38166044)
1. Factors influencing the uptake of a mono-PrEP implant for the prevention of HIV: Males' perspectives from three South African provinces.
Mthimkhulu N; Chidumwa G; Kutywayo A; Mataboge P; Martin CE; Kwatsha K; Makalela N; Mazibuko M; Butler V; Mullick S
PLoS One; 2024; 19(1):e0296341. PubMed ID: 38166044
[TBL] [Abstract][Full Text] [Related]
2. Determinants of heterosexual men's demand for long-acting injectable pre-exposure prophylaxis (PrEP) for HIV in urban South Africa.
Cheng CY; Quaife M; Eakle R; Cabrera Escobar MA; Vickerman P; Terris-Prestholt F
BMC Public Health; 2019 Jul; 19(1):996. PubMed ID: 31340785
[TBL] [Abstract][Full Text] [Related]
3. Preferences, educational messaging, and demand creation channels for multipurpose-prevention technologies (MPTs) among women in South Africa.
Mataboge P; Mthimkhulu N; Kutywayo A; Martin CE; Mazibuko M; Kwatsha K; Makalela N; Briedenhann E; Butler V; Bothma R; Mullick S
BMC Public Health; 2023 Oct; 23(1):2090. PubMed ID: 37880628
[TBL] [Abstract][Full Text] [Related]
4. Design of an Implant for Long-Acting HIV Pre-Exposure Prophylaxis: Input from South African Health Care Providers.
Krogstad EA; Montgomery ET; Atujuna M; Minnis AM; O'Rourke S; Ahmed K; Bekker LG; van der Straten A
AIDS Patient Care STDS; 2019 Apr; 33(4):157-166. PubMed ID: 30932697
[TBL] [Abstract][Full Text] [Related]
5. Key stakeholders' perspectives on providing oral pre-exposure prophylaxis as HIV-prevention standard of care in clinical trials in South Africa.
Beesham I; Milford C; Joseph Davey DL; Smit J; Mansoor LE; Beksinska M
Afr J AIDS Res; 2023 Apr; 22(1):18-26. PubMed ID: 36951406
[No Abstract] [Full Text] [Related]
6. Perspectives of South African youth in the development of an implant for HIV prevention.
Krogstad EA; Atujuna M; Montgomery ET; Minnis A; Ndwayana S; Malapane T; Shapley-Quinn MK; Manenzhe K; Bekker LG; van der Straten A
J Int AIDS Soc; 2018 Aug; 21(8):e25170. PubMed ID: 30152004
[TBL] [Abstract][Full Text] [Related]
7. Understanding Oral PrEP Interest, Uptake, Persistence, and Experience of Use Among Heterosexual Men in Johannesburg, South Africa: An Exploratory Pilot Study.
Felker-Kantor E; Greener LR; Mabaso S; Kruger W; Hasen N; Khosla A; Malone S
AIDS Behav; 2024 Feb; 28(2):564-573. PubMed ID: 38127167
[TBL] [Abstract][Full Text] [Related]
8. Factors that influence adolescent girls and young women's re-initiation or complete discontinuation from daily oral PrEP use: a qualitative study from Eastern Cape Province, South Africa.
de Vos L; Mudzingwa EK; Fynn L; Atujuna M; Mugore M; Gandhi M; Celum C; Hosek S; Bekker LG; Daniels J; Medina-Marino A
J Int AIDS Soc; 2023 Sep; 26(9):e26175. PubMed ID: 37758649
[TBL] [Abstract][Full Text] [Related]
9. Acceptability of a long-acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076).
Tolley EE; Li S; Zangeneh SZ; Atujuna M; Musara P; Justman J; Pathak S; Bekker LG; Swaminathan S; Stanton J; Farrior J; Sista N
J Int AIDS Soc; 2019 Oct; 22(10):e25408. PubMed ID: 31651098
[TBL] [Abstract][Full Text] [Related]
10. Strengthening health system's capacity for pre-exposure prophylaxis for adolescent girls and young women and adolescent boys and young men in South Africa (SHeS'Cap-PrEP): Protocol for a mixed methods study in KwaZulu-Natal, South Africa.
Nicol E; Ramraj T; Hlongwa M; Basera W; Jama N; Lombard C; McClinton-Appollis T; Govindasamy D; Pass D; Funani N; Aheron S; Paredes-Vincent A; Drummond J; Cheyip M; Dladla S; Bedford J; Mathews C
PLoS One; 2022; 17(3):e0264808. PubMed ID: 35298487
[TBL] [Abstract][Full Text] [Related]
11. The Community PrEP Study: a randomized control trial leveraging community-based platforms to improve access and adherence to pre-exposure prophylaxis to prevent HIV among adolescent girls and young women in South Africa-study protocol.
Medina-Marino A; Bezuidenhout D; Hosek S; Barnabas RV; Atujuna M; Bezuidenhout C; Ngwepe P; Peters RPH; Little F; Celum CL; Daniels J; Bekker LG
Trials; 2021 Jul; 22(1):489. PubMed ID: 34311754
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of HIV Pre-exposure Prophylaxis Among Heterosexual Men in South Africa: A Cost-Utility Modeling Analysis.
Vogelzang M; Terris-Prestholt F; Vickerman P; Delany-Moretlwe S; Travill D; Quaife M
J Acquir Immune Defic Syndr; 2020 Jun; 84(2):173-181. PubMed ID: 32141959
[TBL] [Abstract][Full Text] [Related]
13. Epidemiological impact and cost-effectiveness of providing long-acting pre-exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study.
van Vliet MM; Hendrickson C; Nichols BE; Boucher CA; Peters RP; van de Vijver DA
J Int AIDS Soc; 2019 Dec; 22(12):e25427. PubMed ID: 31855323
[TBL] [Abstract][Full Text] [Related]
14. A multi-country cross-sectional study to assess predictors of daily versus on-demand oral pre-exposure prophylaxis in youth from South Africa, Uganda and Zimbabwe.
Dietrich JJ; Ahmed N; Webb EL; Tshabalala G; Hornschuh S; Mulaudzi M; Atujuna M; Stranix-Chibanda L; Nematadzira T; Ssemata AS; Muhumuza R; Seeley J; Bekker LG; Weiss HA; Martinson N; Fox J;
J Int AIDS Soc; 2022 Aug; 25(8):e25975. PubMed ID: 36002910
[TBL] [Abstract][Full Text] [Related]
15. Adolescent-Centered HIV Prevention: Perspectives on Acceptability of Oral Antiretroviral Pre-exposure Prophylaxis for Adolescents in a Global Priority Setting.
Giovenco D; Kuo C; Underhill K; Hoare J; Operario D
Arch Sex Behav; 2021 Oct; 50(7):2921-2931. PubMed ID: 34561792
[TBL] [Abstract][Full Text] [Related]
16. HIV Pre-exposure Prophylaxis Implant Stated Preferences and Priorities: Results of a Discrete Choice Experiment Among Women and Adolescent Girls in Gauteng Province, South Africa.
Little KM; Flomen L; Hanif H; Anderson SM; Thurman AR; Clark MR; Doncel GF
AIDS Behav; 2022 Sep; 26(9):3099-3109. PubMed ID: 35360893
[TBL] [Abstract][Full Text] [Related]
17. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial.
Gill K; Johnson L; Dietrich J; Myer L; Marcus R; Wallace M; Pidwell T; Mendel E; Fynn L; Jones K; Wiesner L; Slack C; Strode A; Spiegel H; Hosek S; Rooney J; Gray G; Bekker LG
Lancet Child Adolesc Health; 2020 Dec; 4(12):875-883. PubMed ID: 33222803
[TBL] [Abstract][Full Text] [Related]
18. Exploring Perceived Barriers and Facilitators of PrEP Uptake among Young People in Uganda, Zimbabwe, and South Africa.
Muhumuza R; Ssemata AS; Kakande A; Ahmed N; Atujuna M; Nomvuyo M; Bekker LG; Dietrich JJ; Tshabalala G; Hornschuh S; Maluadzi M; Chibanda-Stranix L; Nematadzira T; Weiss HA; Nash S; Fox J; Seeley J
Arch Sex Behav; 2021 May; 50(4):1729-1742. PubMed ID: 33954824
[TBL] [Abstract][Full Text] [Related]
19. The Use of HIV Pre-exposure Prophylaxis Among Men Accessing Routine Sexual and Reproductive Health Services in South Africa.
Cox LA; Martin CE; Nongena P; Mvelase S; Kutywayo A; Mullick S
J Adolesc Health; 2023 Dec; 73(6S):S92-S100. PubMed ID: 37953015
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of a community-based delivery model for HIV pre-exposure prophylaxis among bar patrons in rural South Africa.
Grammatico MA; Moll AP; Choi K; Springer SA; Shenoi SV
J Int AIDS Soc; 2021 Nov; 24(11):e25848. PubMed ID: 34826363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
